Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EMB | INO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $2.87 |
52-Week Low | $92.95 | $0.66 |
Market Cap | — | $76.09M |
Enterprise Value | — | $47.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
